drugset / Trial / NCT05964543
The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate safety, tolerability and the efficacy of Q-1802 plus SOC compared with SOC. .Pharmacokinetics (PK) ,Pharmacodynamics (PD) of Q-1802 and the immunogenicity profile of Q-1802 will be evaluated as well.
Timeline
- Start
- 2023-06-21
- Primary completion
- 2024-08-30
- Completion
- 2025-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Q-1802 | Unknown | — | Intravenous |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |